SAN DIEGO, April 6, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company that commercializes and develops liquid biopsy tests for cancer profiling and monitoring, announces that President and CEO Michael W. Nall is scheduled to present a corporate overview at the 15th Annual Needham Healthcare Conference on Wednesday, April 13th, at 1:40 p.m. Eastern time (10:40 a.m. Pacific time). The conference is being held at the Westin Grand Central Hotel in New York City.
A live webcast of the presentation will be available on the investor relations page of the Company's corporate website at ir.biocept.com. A replay of the presentation will be available for 90 days.
Biocept, Inc. is a molecular diagnostics company with commercial tests targeting lung, breast, gastric, colorectal and prostate cancers and melanoma. The company uses its proprietary liquid biopsy technology to provide physicians with more precise information for treating and monitoring patients with cancer. The company's patented Target Selector™ liquid biopsy technology platform captures and analyzes circulating tumor DNA in both circulating tumor cells (CTCs) and in plasma (ctDNA). After thousands of tests, the platform has proven to be effective in identifying cancer biomarker alterations. For additional information, please visit www.biocept.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-to-present-at-the-15th-annual-needham-healthcare-conference-300244470.html
SOURCE Biocept, Inc.